Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Capital Leases (2018 - 2021)

Fulcrum Therapeutics (FULC) has 4 years of Capital Leases data on record, last reported at $2.6 million in Q4 2021.

  • On a quarterly basis, Capital Leases fell 15.37% to $2.6 million in Q4 2021 year-over-year; TTM through Dec 2021 was $2.6 million, a 15.37% decrease, with the full-year FY2021 number at $2.6 million, down 15.37% from a year prior.
  • Capital Leases reached $2.6 million in Q4 2021 per FULC's latest filing, down from $2.7 million in the prior quarter.
  • Over the last five years, Capital Leases for FULC hit a ceiling of $4.0 million in Q4 2018 and a floor of $2.6 million in Q4 2021.
  • A 4-year average of $3.2 million and a median of $3.2 million in 2020 define the central range for Capital Leases.
  • Peak YoY movement for Capital Leases: dropped 11.75% in 2019, then dropped 15.37% in 2021.
  • Tracing FULC's Capital Leases over 4 years: stood at $4.0 million in 2018, then fell by 11.75% to $3.5 million in 2019, then dropped by 13.35% to $3.1 million in 2020, then decreased by 15.37% to $2.6 million in 2021.
  • Business Quant data shows Capital Leases for FULC at $2.6 million in Q4 2021, $2.7 million in Q3 2021, and $2.8 million in Q2 2021.